Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 1.1% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (EW) is a leading company in the medical device industry, particularly known for its innovations in structural heart disease devices. The market for healthcare equipment is showing positive signs of growth and potential.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 1.1% on Feb 11, 2026 16:21

• An affirmation of a "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD has enhanced investor confidence and sparked a bullish movement in the stock.
• Despite falling short of the EPS estimate by $0.04, Edwards Lifesciences delivered robust Q4 2025 sales growth, primarily from TAVR sales, and expressed optimism about its 2026 adjusted EPS and full-year sales growth forecast. This positive outlook has likely contributed to the bullish momentum.
• Strong Q4 2025 results, featuring double-digit revenue growth and positive projections for growth avenues like the LAA market, have reinforced investor confidence in Edwards Lifesciences, adding fuel to the bullish trend.
• Overall, positive analyst ratings, robust sales growth, and a promising future outlook have driven Edwards Lifesciences' stock on an upward trajectory today.

EW Price Chart

EW Technical Analysis

EW News

BTIG Reiterates Buy Rating for Edwards Lifesciences (EW) | EW St

BTIG has reaffirmed its "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD, reflecting confidence in the company's growth potential. This decision aligns with a generally positive outlook from other analysts, who have also maintained or upgraded their ratings and raised target prices for the medical device company. Edwards Lifesciences, a leader in structural heart disease devices, sees an average analyst target price of $96.09, suggesting a potential upside of 24.71% from its current price.

https://www.gurufocus.com/news/8604765/btig-reiterates-buy-rating-for-edwards-lifesciences-ew-ew-stock-news

What To Expect From Artivion's (AORT) Q4 Earnings

Artivion (AORT) is set to report its Q4 earnings this Thursday. Analysts project a 20.2% year-on-year revenue growth to $117 million and adjusted earnings of $0.18 per share. The company has a history of exceeding revenue estimates, and recent peer performance in the healthcare equipment sector offers mixed signals.

https://finviz.com/news/306753/what-to-expect-from-artivions-aort-q4-earnings

Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Strategic Investments

Edwards Lifesciences Corp (EW) reported strong Q4 2025 results with an 11.6% increase in sales and 10.7% for the full year, driven by robust growth in its TAVR and TMTT segments. Despite challenges like higher spending on patient access initiatives and one-time charges impacting EPS, the company maintains a positive outlook with confident 2026 sales and EPS guidance. CEO Bernard Zovighian and CFO Scott Ullem detailed strategic investments and market dynamics, particularly in TAVR and future growth opportunities like the LAA market.

https://www.gurufocus.com/news/8604080/edwards-lifesciences-corp-ew-q4-2025-earnings-call-highlights-strong-sales-growth-amidst-strategic-investments

Edwards Lifesciences (EW) Earnings Transcript

Edwards Lifesciences reported strong Q4 and full-year 2025 results, with double-digit revenue growth driven by their structural heart strategy, particularly TAVR and TMTT product groups. The company is confident in its 2026 sales and EPS guidance, anticipating continued growth from new therapies, expanded indications, and positive clinical evidence, while maintaining a focus on strategic investments and share repurchases.

https://www.theglobeandmail.com/investing/markets/stocks/EW-N/pressreleases/144160/edwards-lifesciences-ew-earnings-transcript/

Edwards Lifesciences misses EPS estimate by $0.04, surpasses revenue prediction

Edwards Lifesciences reported robust Q4 2025 sales growth of 13.3% to $1.57 billion, primarily driven by TAVR sales, but missed Wall Street's EPS estimate by $0.04, reporting $0.58. Despite the EPS miss, the company expressed increased confidence in its 2026 projected adjusted EPS of $2.90 to $3.05 and full-year sales growth guidance of 8-10%, driven by updated European TAVR guidelines, potential CMS coverage changes, and new product introductions. Investors reacted positively to the 2026 guidance, with shares rising in after-hours trading.

https://www.massdevice.com/edwards-lifesciences-misses-eps-estimate-by-0-04-surpasses-revenue-prediction/

Trending Today

Aave ($AAVE) Crypto Forecast: Down 5.8% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.2% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.0% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

Edwards Lifesciences Corporation Price History

31.09.2025 - EW Stock was up 0.6%

• The bullish movement in Edwards Lifesciences (EW) stock today can be attributed to:
• Positive analyst upgrades indicating a favorable outlook on the company's performance.
• Anticipation and optimism surrounding the upcoming Q3 earnings report, with analysts projecting strong results.
• The news of an investigation by a law firm may have had a minimal impact on the market movement, as investors focused more on the positive analyst upgrades and earnings projections.

28.09.2025 - EW Stock was up 7.2%

• The optimistic movement in EW stock can be linked to favorable analyst estimates for its Q3 earnings, indicating strong performance and potential growth outlook.
• Despite ongoing investigations into potential breaches of fiduciary duties by EW's directors and officers, investors maintain a positive outlook on the company's future, influencing the bullish market trend.
• Investor confidence appears to be driven by the company's solid fundamentals and growth prospects rather than the legal scrutiny, resulting in the upward movement of the stock price.

24.03.2025 - EW Stock was up 7.2%

• Strong bullish movement in the stock today.
• Analysts upgraded the stock as the growth outlook brightened, with Q1 sales rising 58% YoY and beating consensus estimates.
• Q1 earnings and revenues surpassed expectations, leading to a raised sales view for 2025.
• The market responded positively to the company's performance and optimistic outlook, driving the stock price higher.

24.03.2025 - EW Stock was up 5.0%

• Q1 earnings and revenues of Edwards Lifesciences (EW) surpassed expectations, resulting in a surge in the stock price.
• The company's unique portfolio of therapies likely played a role in its strong market performance.
• An increased sales outlook for 2025 reflects positive market sentiment and confidence in the company's future growth.
• Analysts are delving into various key metrics beyond standard estimates, indicating a profound understanding of Edwards Lifesciences' potential for sustained success.

25.06.2025 - EW Stock was up 3.9%

• Edwards Lifesciences (EW) saw a significant uptrend in the market today.
• This rise is linked to the company outperforming expectations in their second-quarter financial results, exceeding projected earnings.
• Additionally, analysts raised their forecasts for EW following the strong Q2 results, further boosting investor confidence.
• The positive market response to the company's strong performance and positive outlook led to an increase in the stock price.

25.06.2025 - EW Stock was up 6.6%

• Q2 results for Edwards Lifesciences (EW) are believed to have surpassed expectations from analysts.
• The company's strong performance in key metrics may have boosted investor confidence, influencing the bullish movement.
• The robust Q2 performance could signal innovation and market responsiveness, attracting more investors and potentially increasing the stock price.

25.06.2025 - EW Stock was up 5.2%

• Edwards Lifesciences (EW) experienced a strong bullish movement today following its Q2 earnings report.
• The company reported Q2 sales of $1.53 billion, surpassing the estimated $1.49 billion, and an EPS of $0.67, higher than the expected $0.62.
• The positive results were primarily driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments.
• Analysts have increased their forecasts for EW after the robust Q2 results, with a price target also being raised to $101 on the company's growth momentum. The raised FY25 sales outlook further contributed to the bullish sentiment surrounding the stock.

28.00.2025 - EW Stock was up 5.0%

• Analysts predict a decrease in earnings for Edwards Lifesciences, but significant investment in the company's options indicates a positive market sentiment.
• The discrepancy between analyst forecasts and market behavior suggests investor anticipation of future growth or positive company developments.
• The rise in EW's stock price may be linked to the confidence displayed by high-stakes investors in the company's future potential, leading to increased purchasing activity and driving up the stock value.
• Investor interest in Edwards Lifesciences appears driven by a focus on long-term growth prospects and the company's market positioning, rather than short-term earnings forecasts.

11.01.2026 - EW Stock was up 1.1%

• An affirmation of a "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD has enhanced investor confidence and sparked a bullish movement in the stock.
• Despite falling short of the EPS estimate by $0.04, Edwards Lifesciences delivered robust Q4 2025 sales growth, primarily from TAVR sales, and expressed optimism about its 2026 adjusted EPS and full-year sales growth forecast. This positive outlook has likely contributed to the bullish momentum.
• Strong Q4 2025 results, featuring double-digit revenue growth and positive projections for growth avenues like the LAA market, have reinforced investor confidence in Edwards Lifesciences, adding fuel to the bullish trend.
• Overall, positive analyst ratings, robust sales growth, and a promising future outlook have driven Edwards Lifesciences' stock on an upward trajectory today.

27.09.2025 - EW Stock was up 5.8%

• The bullish movement in EW stock could be attributed to an investigation into potential breaches of fiduciary duties by the company's directors and officers.
• Investors may interpret this investigation as a sign of accountability and transparency within the company, leading to increased confidence in EW's corporate governance practices.
• This news might have reassured shareholders and attracted new investors, contributing to the positive market movement of EW stock today.

12.01.2025 - EW Stock was up 6.6%

• The company reported strong Q4 sales growth, surpassing consensus estimates and showing a 9% increase year-over-year.
• TMTT sales surged by 77% in 2023, driven by the adoption of PASCAL and EVOQUE, significantly contributing to the positive overall performance.
• TAVR sales performed robustly, reaching $1.04B in Q4 with a 5.3% increase year-over-year, additionally boosting the stock's positive movement.
• Analysts remain confident in Edwards Lifesciences' long-term prospects, which is evident in the positive market sentiment and today's bullish stock movement.

01.09.2025 - EW Stock was down 3.7%

• The bearish movement in Edwards Lifesciences stock today could be attributed to:
• Profit-taking by investors after a prolonged period of outperformance in the market.
• Concerns about potential competition or regulatory challenges in the medical technology sector.
• Overall market sentiment affecting healthcare stocks, leading to a broader sell-off in the industry.
• Technical factors triggering a short-term downward trend in the stock price.